Source: The Pharma Letter

Myovant Sciences: FDA accepts NDA for relugolix combo for uterine fibroids

Switzerland-based Myovant Sciences (NYSE: MYOV) says that its New Drug Application (NDA) for once-daily,...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating

89/100

Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more